source
- GSK receives FDA approval for ROS1 inhibitor Jideytro, marking its first lung cancer drugGSK's FDA approval of Jideytro, a ROS1 inhibitor for advanced non-small cell lung cancer patients with ROS1 gene fusions who have already received ROS1-directed therapy, was announced on Wednesday.…
- Most FDA-approved drugs meet postmarketing study requirements, and advisory panel backs two peptides for bulk compoundingA recent analysis published in JAMA Network Open found that nearly nine out of ten drugs approved by the U.S. Food and Drug Administration have completed their postmarketing requirements or commitm…